Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Besse

Showing results (341-350 of 512) with videos related to

Pageof 52
Sort By:
The Lancet. Oncology|November 1, 2019
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trialAlice T Shaw, Benjamin J Solomon, Rita Chiari, et al.
Autoimmunity Reviews|January 10, 2020
Systemic lupus erythematosus associated with thymoma: A fifteen-year observational study in FranceNicolas Noël, Audrey Le Roy, Arnaud Hot, et al.
Nature Reviews. Clinical Oncology|March 15, 2025
Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trialsSophie M Ernst, Mihaela Aldea, Jan H von der Thüsen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2024
Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven MalignanciesFrancesco Facchinetti, Yohann Loriot, Floriane Brayé, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 2, 2010
A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lungNatasha B Leighl, Luis E Raez, Benjamin Besse, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2014
Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTEMarie Wislez, Fabrice Barlesi, Benjamin Besse, et al.
European Journal of Cancer (Oxford, England : 1990)|October 28, 2023
Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancerClara Helal, Cédric Pobel, Arnaud Bayle, et al.
ERJ Open Research|February 17, 2018
Real-life experience of ceritinib in crizotinib-pretreated <i>ALK</i><sup>+</sup> advanced non-small cell lung cancer patientsJacques Cadranel, Alexis B Cortot, Hervé Lena, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2021
Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicitiesSamia Hajem, Stéphane Ederhy, Stéphane Champiat, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 21, 2019
Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal MetastasesRonan Flippot, Pamela Biondani, Edouard Auclin, et al.
Pageof 52

Showing results (341-350 of 512) with videos related to

Sort By:
Pageof 52
The Lancet. Oncology|November 1, 2019
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trialAlice T Shaw, Benjamin J Solomon, Rita Chiari, et al.
Autoimmunity Reviews|January 10, 2020
Systemic lupus erythematosus associated with thymoma: A fifteen-year observational study in FranceNicolas Noël, Audrey Le Roy, Arnaud Hot, et al.
Nature Reviews. Clinical Oncology|March 15, 2025
Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trialsSophie M Ernst, Mihaela Aldea, Jan H von der Thüsen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2024
Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven MalignanciesFrancesco Facchinetti, Yohann Loriot, Floriane Brayé, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 2, 2010
A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lungNatasha B Leighl, Luis E Raez, Benjamin Besse, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2014
Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTEMarie Wislez, Fabrice Barlesi, Benjamin Besse, et al.
European Journal of Cancer (Oxford, England : 1990)|October 28, 2023
Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancerClara Helal, Cédric Pobel, Arnaud Bayle, et al.
ERJ Open Research|February 17, 2018
Real-life experience of ceritinib in crizotinib-pretreated <i>ALK</i><sup>+</sup> advanced non-small cell lung cancer patientsJacques Cadranel, Alexis B Cortot, Hervé Lena, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2021
Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicitiesSamia Hajem, Stéphane Ederhy, Stéphane Champiat, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 21, 2019
Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal MetastasesRonan Flippot, Pamela Biondani, Edouard Auclin, et al.
Pageof 52